Nephrotic Syndrome
Nephrotic Syndrome
Nephrotic Syndrome
diagnosis?
Guess the
diagnosis?
NEPHROTIC
SYNDROME
Dr TRIPTI SRIVASTAVA
MD PAEDIATRICS
AP
DEPARTMENT OF PEDIATRICS
VCSG INSTITUTE OF MEDICAL SCIENCES
HOPI:
Mayank, a 6-year old male child, hindu by religion s/o Ashish
Kumar, resident of village- Vyaschatti, distict Pauri Garhwal was
2. Fever×1 day
3. Loose stools (3 episodes )×1 day
As stated by the patient’s attendant( father ), he was apparently
asymptomatic 3 days back when he started developing swelling
around eyes and face which was progressive and increased to
extend up to abdomen. There was no history of diurnal variation.
HOPI The patient also developed fever 1 day back, acute in onset,
continuous , not documented, not associated with chills or rigor.
The patient also had 3 episodes of loose stools, watery in
consistency , not associated with blood or mucous.
No history of vomitings, cough, sore throat,difficulty in breathing,
palpitations, chest pain,bluish discoloration
No history of decease in urine volume and frequency
No history of jaundice, blood in urine, burning micturition, cola
coloured urine.
HOPI No history of headache, altered sensorium, seizures.
No history of recurrent infection, skin rashes ,boils, joint pain,
weight loss.
No history of drug intake.
No history of insect bite.
PAST HISTORY:
Patient presented with similar complaints in May 2021, was
admitted in this hospital diagnosed and treated as a case of
Steroid sensitive Idiopathic Nephrotic syndrome. Patient had
similar episode in May 2022,was admitted and treated in our
HISTORY hospital as first relapse.
FAMILY HISTORY:
No history of similar complaints in other family members.
No history of DM, TB, HTN , obesity,allergies ,asthma or any other
chronic renal illness.
No history of consanguineous marriage.
ANTENATAL AND NATAL HISTORY :
Uneventful ( Term/AGA/ NVD/ immediate cry) G3P3L3A0
DEVELOPMENTAL HISTORY:
Appropriate for age
IMMUNISATION HISTORY:
Complete for age as per NIS
Pneumococcal, influenza and varicella vaccines not administered
after previous both episodes
ANTHROPOMETRY
SYSTEMIC EXAMINATION
INCIDENCE Occurs at all ages but is most prevalent in children between the
ages 1.5-6 years.
Membranous Nephropathy(rare )
Membranoproliferative glomerulonephritis
Features Minimal Lesion Significant Lesion
Age 2-6 years Older
Sex > In Boys Equal
Hematuria Minimal Usual
Edema Significant always Less significant
Blood Pressure Normal Normal or Increased
GFR Normal Normal or Decreased
Renal Biopsy
Light Microscopy- No significant Sclerosis in glomerular tuft
Immunoglobulin deposits / C3
Electron Microscopy- Non specific obliteration of foot
processes
Hypoalbuminemia
Beta - LipoProteins
Enhances
Na – H2O Retention
Primary sodium retention (due to epithelial sodium channel in distal
tubule)
IV albumin 5% or 20%
Fluid Overload If Renal
Side Effects of Dysfunction
IV Albumin Pulmonary Edema
Specific treatment ---
Corticosteroid therapy with Prednisolone or
prednisone – ( 2mg/kg per day or 60 mg/m2/day for 6 weeks followed by 1.5
mg/kg /40mg/m2single morning dose on alternate days for 6 weeks ) not on empty
stomach , BD or OD dosing
Remission occurs usually 10-14 days after starting therapy.
Remission Urine protein nil or trace (Up/Uc <0.2 mg/mg) for 3 consecutive early morning
specimens
Relapse Urine protein >3+ (Up/Uc >2 mg/mg) for 3 consecutive early morning
specimens, having been in remission previously
Frequent Relapses Two or more relapses in the first 6-months after stopping initial Therapy or
(50% cases) during initial therapy ; ≥3 relapses in any 6-months; or ≥4 relapses in one yr
1
Steroid dependence Two consecutive relapses when on alternate day steroids, or within 14 days of
its discontinuation
Steroid Resistance Lack of complete remission despite therapy with daily prednisolone at a dose
(3-10% cases) of 2 mg/kg (or 60 mg/m2) daily for 6 weeks
Difficult to Treat Steroid Both of the following: (i) frequent relapses, or significant steroid toxicity
Sensitive Disease with infrequent relapses; and (ii) failure of ≥2 steroid sparing agents
(including levamisole, cyclophosphamide, mycophenolate mofetil)
Parent Education
Symptomatic therapy for infections in case of low grade
MANAGEMENT proteinuria (1+ - 2+)
If Persistent high grade proteinuria ( 3+ - 4+ ) – –
OF Prednisolone ( 2mg/kg/day or 60 mg/m2/day until
INFREQUENT protein is negative/trace for 3 consecutive days )
RELAPSE Followed by 1.5 mg/kg or 40 mg/m2 on alternate
days for 4 weeks )
Treatment lasts for 5-6 weeks.
Features of Hypovolemia during Relapse of Nephrotic Syndrome
Clinical Features
Abdominal Pain , Vomiting , Lethargy
Prolonged CFT , Cold Extremities
Tachycardia , Low volume Pulse
Low Blood pressure, Postural Hypotension
Biochemical Indices
Elevated Hematocrit
Fractional excretion of Sodium <0.5%
Urinary Potassium index (Urine K+/Urine Na+K) > 0.6
Ultrasonography – Decreased Inferior vena cava diameter , Increased Collapsibility index (110)
Frequently relapsing, steroid dependent nephrotic syndrome
FREQUENT days
>1 complicated relapse
RELAPSES No
Significant steroid toxicity
Yes Mycophenolate mofetil(high
Frequent dose
Levamisole Relapses Cyclophosphamide
Mycophenolate mofetil Difficult - to-Treat
(low dose) Disease
Cyclosporine, tacrolimus
Rituximab
Medication Dose Duration Adverse Effects Recommended Monitoring
Prednisolone 0.5-0.7 mg/kg on 6-12 Cushingoid features; Short stature hypertension hypertension
alternate day months raised intraocular pressure Anthropometry q 3-6 mo;
Glucose intolerance cataract ,elevated eye evaluation q 6-12 month; blood
Transaminases sugar and transaminases q 3-6 month
Levamisole 2-2.5 mg/kg on 2-3 years Leukopenia, ANCA positive vasculitis, high Blood counts q 2-3 month;
Alternate day transaminases, Seizures transaminases q 4-6 month
Cyclo-Phosphamide 2-2.5 mg/kg/day 8-12 week Leukopenia, alopecia, infections; discolored nails; Blood counts q 2 weeks
orally hemorrhagic cystitis; gonadal toxicity and Maintain hydration; discontinue during
malignancies significant infections Co-administer with
prednisolone 1 mg/kg AD
Mycophenolate 600-1200 2-3 Abdominal pain, diarrhea, nausea, weight loss; Screen for adverse effects
Mofetil mg/m2/day in years viral warts; Blood counts and
divided doses; AUC leukopenia; elevated transaminases transaminases q 3-6 mo
>45 mg·h/L
Cyclosporine 4-5 mg/kg/day 2-3 Both: Nephrotoxicity, hyperkalemia, Screen for cosmetic side
in divided doses; years hepatotoxicity effects, tremors, diarrhea,
trough 80-120 Cyclosporine: Gingival hyperplasia, hypertrichosis; hypertension
ng/mL hypertension; dyslipidemia,6H Creatinine, potassium at 2-4 weeks, q 3-
Tacrolimus: Tremors, seizures, headache; diarrhea; 6 mo
Tacrolimus 0.1-0.2mg/kg/d in 2-3 glucose intolerance; hypomagnesemia Liver function tests, glucose, uric acid,
divided doses; years magnesium and lipids q 3-6 mo
trough 4-8 ng/mL
Rituximab 375 mg/m2, slow IV 2 doses, Chills, fever; serum sickness; bronchospasm ,Acute lung Pre dose: Blood counts,
infusion 1-week injury ,Neutropenia;P. jirovecii pneumonia; reactivation of transaminases; hepatitis
apart hepatitis B or JC virus; Hypogammaglobulinemia and HIV serology; immunoglobulin G (IgG) level
Post therapy: CD19 counts; blood counts; IgG;
consider cotrimoxazole prophylaxis
Cyclophosphamide is avoided in Children (<5-7
year old) due to reduced efficacy & in Peri-
Pubertal Boys due to Risk of Gonadal Toxicity.
S • Meningitis
• Sepsis
Rx -Antibiotics , Acyclovir, Vaccines when off steroid for 4 weeks
3) Thrombotic complications – Cerebral , Pulmonary , Renal vein
thrombosis.
Rx-LMWH & Oral anticoagulants.
Aggressive use of diuretics, Venipuncture of deep veins (brachial,
femoral), Hypovolemia
4)Hypovolemia and Acute renal Failure
5)Steroid Toxicity
Management of Serious Infections
Infections Organism Diagnosis Treatment
Peritonitis S.Pneumoniae Ascitic fluid >100 cells/mm3 Ceftriaxone or Cefotaxime for 7-10
S.Pyogenes >50% neutrophils days
E.Coli Ascitic fluid – Culture , Latex Ampicillin and
Gram –ve bacteria agglutination, PCR Gentamicin/Amikacin for 7-10 d
Pneumonia S, Pneumoniae , S.aureus Chest Xray, Blood culture, Sputum Oral- Amoxicillin, Coamoxiclav,
H.Influenzae , for gram stain & culture cefuroxime * 10-14 days
IV Ceftriaxone & Amikacin *7-10d
H1N1 influenza Throat swab for H1N1 Oseltamivir for 5 days
M.tuberculosis Tuberculin test, pleural tap, Therapy as per NTEP
gastric aspirate, Sputum CBNAAT
Cellulitis S.Aureus , S.pyogenes Pus for culture, Sensitivity , Blood IV Coamoxiclav , Cloxacillin with
H. Influnzae culture Ceftriaxone * 7-10 days
Gram –ve bacteria
Sepsis S.Pneumoniae , Gram –ve CBC , CRP Ceftriaxone & Amikacin * 10-14 days
bacteria Procalcitonin , Blood culture
Receing high dose prednisolone (>2mg/kg/d , >20 Vaccinate 1 month after discontinuing
mg/day if >10kg) for >14 days corticosteroids
Receiving low-moderate dose Prednisolone (<2 No live vaccines , until discontinuation of steroid
mg/kg/d or equivalent , <20 mg/d ) therapy
Low dose alternate day prednisolone and pressing Live vaccine may be administered
need for Vaccine
Pateints receiving Cyclophosphamide Avoid live vaccines until off therapy for 3 months
Patients receiving Calcineurin inhibitors , Avoid live vaccines until off therapy for 1 month
Levamisole or Mycophenolate mofetil
Therapy with Rituximab Avoid live vaccines until after B-cell recovery (6-9
months)
Immunocompetent siblings & household contacts Do not administer OPV , may receive MMR ,
Rotavirus & Varicella vaccine
Household contacts older than one year Administer influenza vaccine annually
Specific Vaccines for Patients with Nephrotic Syndrome
Vaccine Age Previously received Vaccine Schedule
Pneumococcal 6-72 Completely immunized (3 PCV 13/10 One dose >2 year old
Conjugate (PCV , months doses at 6,10 & 14 weeks ,
13 valent booster at 12-15 months) PPSV23 One dose when >2 year old & >8
preferred to 10 week after last PCV 13/10 dose
valent) Incompletely immunized PCV 13/10 2 doses , >8 weeks apart
Polysaccharide
(23 valent , PPSV23 1 dose when >2 year old & >8
PPSV23) week after last PCV 13/10 dose
>6 years Completely immunized PPSV23 1 dose
Incompletely immunized PCV 10/13 1 dose
PPSV23 1 dose >8 weeks after last
PCV13/10 dose
Varicella >15 months No evidence of immunity Live 2 doses 4-8 weeks apart
Attenuated
Influenza >6 months Inactivated Anually
Hepatitis B Any No , or Anti-HBs Subunit 3 doses at 0,1 & 6 months, or in
<10mIU/mL (10 microG/0.5 accelerated schedule with >4
mL) week gap between doses 1 & 2 ,
>8 week between doses 2&3 , &
>16 week between dose 1 & 3
THANK YOU